Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06765603

Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression

The aim of the study is to explore efficacy of combination Atropine and multifocal CL. Randomized Control Trial including 4 arms: Atropine / multizonal CL; Atropine/ SV CL, Placebo drop/ multizonal CL; Placebo drop/ SV CL. Followed over 1 year with outcome measure of change in spherical equivalent and axial length.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

7 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

About this study

see above

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 7 and 12 (inclusive) years of age at the time of screening.
  • spherical equivalent of cycloplegic objective refraction (by autorefraction) range of -0.75 D to -4.50 D (inclusive) in each eye.
  • Refractive cylinder less than 1.12 D (inclusive)
  • Best-corrected visual acuity (BCVA) of 0.04 logMAR or better in each eye, with difference less than 0.20 logMAR between eyes.
  • Have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion criteria

  • Past or current use of myopia control treatment or involvement in previous myopia control study
  • Any current or seasonal use of ocular medication (eg. for allergy or chronic blepharitis).
  • hypersensitivity or allergic reaction to atropine, cyclopentolate, topical anesthetics or study approved rewetting drop solutions available in local markets.
  • previous history or signs of a contact lens-related corneal inflammatory event (e.g., past ulcer or scar) that may contraindicate contact lens wear.
  • Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, ocular hypertension, glaucoma, history of recurrent corneal erosions, aphakia, uveitis, severe keratoconjunctivitis sicca, keratoconus, keratoconus suspect, and pellucid marginal degeneration.
  • Grade 3 or greater palpebral conjunctival observations or any other Grade 2 or greater slit-lamp findings (eg. edema, corneal neovascularization, corneal staining, conjunctival injection) on the ISO 11980 classification scale.
  • Any central corneal scar or corneal distortion resulting from ocular diseases or previous hard or rigid permeable contact lens wear.

Treatment and study plan

Atropine 0.025%

Drug

Atropine 0.025%

Multizonal contact lens

Device

Multizonal CL

Placebo

Drug

Placebo

Single vision Contact lens

Device

Single vision contact lens

Primary outcomes

  1. Change in spherical equivalent

    Time frame: 12 months

    Change in spherical equivalent at 12 months

Secondary outcomes

  1. Change in axial length

    Time frame: 12 months

    Change in axial length at 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

audrey chia, PhD

CONTACT

[email protected]

65 62277255

Sponsors and collaborators

Lead sponsor

Singapore National Eye Centre

Other Gov

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Jan 9, 2025
Registry last updated
Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.